Experience with tranexamic acid, an indirect fibrinolytic inhibitor, started as soon as it was
released from Shosuke Okamoto's lab in the early 1960s. It was first prescribed to females …

Tranexamic acid (TXA) is an antifibrinolytic agent commonly used for the treatment or
prevention of bleeding. Indications for TXA are diverse, including heavy menstrual bleeding …

Aim Tranexamic acid (TXA) is a synthetic anti‐fibrinolytic agent commonly used for the
prevention and treatment of bleeding disorders. The aim of this study is to describe the …

The authors found a dose-dependent surgical site infection risk in blood-transfused patients
and hypothesised that those undergoing knee arthroplasty who receive multiple doses of …

Antecedentes: En la poliquistosis renal autosómica dominante (PQRAD), la hematuria
macroscópica por la rotura de quistes renales es una manifestación habitual, que puede ser …

Therapeutic anticoagulation remains a fundamental backbone in the treatment and
prevention of venous thromboembolism. However, while modern therapies are increasingly …

Abstract Background/Aims: In this retrospective study we aimed to compare the effect of
tranexamic acid (TXA) vs etamsylate, two hemostatic agents, on hematuria duration in …

The interaction between the kidney and the coagulation system greatly affects each other
because of the abundant vessel distribution and blood perfusion in the kidney. Clinically, the …

TORREGROSA, José V. et al. Tratamiento eficaz de la arteriolopatía urémica calcificante
con bifosfonatos. Nefrología (Madr.)[online]. 2012, vol. 32, n. 3, pp. 329-334. ISSN 0211 …

Gross hematuria is common in autosomal dominant polycystic kidney disease (ADPKD). It is
an alarming symptom and may be the first manifestation of ADPKD. Cyst hemorrhage is a …